Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

about

Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.

P2860

Q34860261-F50B5D26-EAA5-4B66-A3C7-6B42C7592683 Q42723586-A423F723-DD69-442C-B909-B799CECB7CCA

P2860

Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

Item

http://www.wikidata.org/entity/Q39538576

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Study reanalysis using a mecha ...... subjects with type 1 diabetes.

@en

Study reanalysis using a mecha ...... subjects with type 1 diabetes.

@nl

type

Item

label

Study reanalysis using a mecha ...... subjects with type 1 diabetes.

@en

Study reanalysis using a mecha ...... subjects with type 1 diabetes.

@nl

prefLabel

Study reanalysis using a mecha ...... subjects with type 1 diabetes.

@en

Study reanalysis using a mecha ...... subjects with type 1 diabetes.

@nl

P1476

Study reanalysis using a mecha ...... subjects with type 1 diabetes.

@en

P2093

Brenda Cirincione

http://www.w3.org/2001/XMLSchema#string

Cornelia B Landersdorfer

http://www.w3.org/2001/XMLSchema#string

Jing Fang

http://www.w3.org/2001/XMLSchema#string

William J Jusko

http://www.w3.org/2001/XMLSchema#string

P2860

Pramlintide in the treatment of type 1 and type 2 diabetes mellitus

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Ways to fit a PK model with some data below the quantification limit.

Full-length rat amylin forms fibrils following substitution of single residues from human amylin.

A system model of oral glucose absorption: validation on gold standard data.

An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.

Impact of censoring data below an arbitrary quantification limit on structural model misspecification.

Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells.

Highly variable gastric emptying in patients with insulin dependent diabetes mellitus.

P2888

s12248-012-9409-7

P304

15-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-012-9409-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232231600

http://www.w3.org/2001/XMLSchema#string

P6179

1009286747

http://www.w3.org/2001/XMLSchema#string

P698

23054970

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3535104

http://www.w3.org/2001/XMLSchema#string

Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

about

P2860

P2860

Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P921

P932